Once-Weekly Semaglutide in Adolescents with Obesity
Paracelsus Medical University · University of Birmingham · +6 more institutions
Indexed incrossrefpubmed
Abstract
Background
A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist, is used to treat obesity in adults, but assessment of the drug in adolescents has been lacking.
Methods
In this double-blind, parallel-group, randomized, placebo-controlled trial, we enrolled adolescents (12 to
Citation impact
608
total citations
- FWCI
- 69.76
- Percentile
- 100%
- References
- 28
Citations per year
Authors
10- DWDaniel WeghuberCorresponding
Paracelsus Medical University
- TBTimothy Barrett
Paracelsus Medical University, University of Birmingham
- MBMargarita Barrientos‐Pérez
Paracelsus Medical University
- IGInge Gies
Paracelsus Medical University, Universitair Ziekenhuis Brussel
- DHDan Hesse
Novo Nordisk (Denmark), Paracelsus Medical University
Topics & keywords
Topics
Keywords
- Semaglutide
- Agonist
- Obesity
- Medicine
- Internal medicine
- Endocrinology
- Receptor
- Diabetes mellitus
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.